-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
The company has been honored with multiple accolades, including “Top 100 Chinese Pharmaceutical Industries.”
Category:
Time：2019-07-15
Recently, the “2018 China Pharmaceutical Industry’s Most Influential List Release Ceremony and the 11th China (Jinan) Pharmaceutical Industry Development Summit Forum,” supported by the All-China Federation of Industry and Commerce, organized by the Pharmaceutical Industry Chamber of the ACFC, and hosted by the Jinan Federation of Industry and Commerce and the Jinan Municipal Health Commission, with co-organization by the Shandong Pharmaceutical Chamber of Commerce, was successfully held in Jinan, Shandong Province. The event attracted extensive attention from both the pharmaceutical industry and broader society. The annual release of the “China Pharmaceutical Industry’s Most Influential List” has been held for five consecutive years and has become a prestigious annual event in China’s pharmaceutical sector. The selection process for the awards involves an expert panel composed of top domestic scholars and specialists, adhering to the principle of “openness.”
Recently, the “2018 China Pharmaceutical Industry’s Most Influential List Release Ceremony and the 11th China (Jinan) Pharmaceutical Industry Development Summit Forum,” supported by the All-China Federation of Industry and Commerce, organized by the Pharmaceutical Industry Chamber of the ACFC, and hosted by the Jinan Federation of Industry and Commerce and the Jinan Municipal Health Commission, with co-organization by the Shandong Pharmaceutical Chamber of Commerce, was successfully held in Jinan, Shandong Province. The event attracted extensive attention from both the pharmaceutical industry and broader society.
The annual list of China’s Most Influential Players in the Pharmaceutical Industry has been held for five consecutive years, making it a premier brand event in China’s pharmaceutical sector. The award selection process invites top domestic experts and scholars to form a judging panel, adhering to the principles of “open solicitation, objective data, rigorous screening, and fair evaluation.” As a result, the “2018 List of China’s Most Influential Players in the Pharmaceutical Industry” has been finalized, featuring leading enterprises from all sectors of the pharmaceutical industry. Thanks to its high-quality development achievements over the past few years, the company has been honored with two prestigious awards: “Top 100 Chinese Pharmaceutical Manufacturers” and “Top 50 Growing Companies in China’s Pharmaceutical Industry.”
Behind the honors lies the unwavering commitment of the employees of Siyao to uphold our original aspiration of green pharmaceuticals, firmly keeping in mind our dedication and pursuit of a Healthy China. As a large-scale, comprehensive pharmaceutical enterprise in China, the company has consistently adhered to its corporate mission of prioritizing quality, caring for the people, and acting with integrity. We place great emphasis on research and development and value meticulous management, leveraging our technological strengths to devote ourselves to product R&D and manufacturing, thereby providing the public with high-quality, safe medications. Through more than 70 years of relentless efforts, the company has earned widespread recognition from national, industry, and societal circles. In 2018, the company achieved a 33% year-on-year increase in sales revenue and a 34.2% year-on-year rise in net profit, maintaining robust growth momentum and effectively playing a leading role in driving the industry forward, thus making positive contributions to the development of the local economy.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license